The ADAMs family of proteases: New biomarkers and therapeutic targets for cancer?

Clinical Proteomics

Volumn 8, Issue 1, 2011, Pages

  Duffy, Michael J ^a,b   Mullooly, Maeve ^a,b   O'Donovan, Norma ^c   Sukor, Sumainizah ^a,b   Crown, John ^a   Pierce, Aisling ^a,b   McGowan, Patricia M ^a,b  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

^c DUBLIN CITY UNIVERSITY   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ADAM PROTEIN; ADAM10 ENDOPEPTIDASE; ADAM11 ENDOPEPTIDASE; ADAM12 ENDOPEPTIDASE; ADAM15 ENDOPEPTIDASE; ADAM22 ENDOPEPTIDASE; ADAM9 ENDOPEPTIDASE; ADERBASIB; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEFITINIB; GI 254023X; GW 280264X; GW 2974; GW280264X; INCB 3619; INCB3619; JANUS KINASE; KB R7785; LAPATINIB; MATRIX METALLOPROTEINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; STAT PROTEIN; TMI 2; TRANSFORMING GROWTH FACTOR BETA; TRASTUZUMAB; TUMOR MARKER; UNCLASSIFIED DRUG; WAY 022;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BONE MARROW TOXICITY; BREAST CANCER; CANCER GROWTH; CANCER INHIBITION; CANCER PROGNOSIS; CARDIOMYOPATHY; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; DIAGNOSTIC TEST; DRUG ERUPTION; DRUG POTENTIATION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MUSCULOSKELETAL DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; PROTEIN TARGETING; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; UNSPECIFIED SIDE EFFECT;

EID: 84860641102     PISSN: 15426416     EISSN: 15590275     Source Type: Journal    
DOI: 10.1186/1559-0275-8-9     Document Type: Review

References (80)

1. The ADAM metalloproteinases. Edwards DR, Handsley MH, Pennington CJ, Mol Aspects Med 2008 29 258 89 10.1016/j.mam.2008.08.001 18762209
2. The ADAMs: Signaling scissors in the tumour microenvironment. Murphy G, Nat Rev Cancer 2008 8 929 41 19005493
3. ADAMS: key components in EGFR signalling and development. Blobel CP, Nature Rev Cancer 2005 6 32 43 (Pubitemid 40064897)
4. Role of ADAMs in cancer formation and progression. Duffy MJ, McKiernan E, O'Donovan N, McGowan P, Clin Cancer Res 2007 13 2335 2343 10.1158/1078-0432. CCR-06-2092 17438092 (Pubitemid 46698582)
5. The role of ADAMs in disease pathophysiology. Duffy MJ, McKiernan E, O'Donovan N, McGowan P, Clin Chim Acta 2009 403 31 36 10.1016/j.cca.2009.01.007 19408347
6. Inhibition of tumor necrosis factor - converting enzyme by its prodomain. Gonzales PE, Solomon A, Miller AB, et al. J Biol Chem 2004 279 31638 31645 10.1074/jbc.M401311200 15100227 (Pubitemid 39037834)
7. The Biology of integrins. Stupack DG, Oncology [Williston Park] 2007 21 6 12
8. ADAMs, cell migration and cancer. Arribas J, Bech-Serra JJ, Santiago-Josefat B, Cancer Met Rev 2006 25 57 68 10.1007/s10555-006-7889-6 (Pubitemid 43723982)
9. Breaking up the tie: disintegrin-like metalloproteinases as regulators of cell migration in inflammation and invasion. Reiss K, Ludwig A, Saftig P, Pharmacol Ther 2006 111 985 1006 10.1016/j.pharmthera.2006.02.009 16626807 (Pubitemid 44118440)
10. Functional analysis of the domain structure of tumor necrosis factor-alpha converting enzyme. Reddy P, Slack JL, Davis R, J Biol Chem 2000 275 14608 14 10.1074/jbc.275.19.14608 10799547 (Pubitemid 30339751)
11. Adam meets Eph: an ADAM substrate recognition module acts as a molecular switch for ephrin cleavage in trans. Janes PW, Saha N, Barton WA, et al. Cell 2005 123 291 304 10.1016/j.cell.2005.08.014 16239146 (Pubitemid 41457218)
12. Extracellular signal-regulated kinase phosphorylates tumor necrosis factor alpha-converting enzyme at threonine 735: a potential role in regulated shedding. Díaz-Rodríguez E, Montero JC, Esparís-Ogando A, Yuste L, Pandiella A, Mol Biol Cell 2002 13 2031 44 10.1091/mbc.01-11-0561 12058067 (Pubitemid 34651490)
13. Direct activation of TACE-mediated ectodomain shedding by p38 MAP kinase regulates EGF receptor-dependent cell proliferation. Xu P, Derynck R, Mol Cell 2010 37 551 566 10.1016/j.molcel.2010.01.034 20188673
14. Phosphorylation-dependent interactions between ADAM15 cytoplasmic domain and Src family protein-tyrosine kinases. Poghosyan Z, Robbins SM, Houslay MD, et al. J Biol Chem 2002 277 4999 5007 10.1074/jbc.M107430200 11741929 (Pubitemid 34968539)
15. Targeting TACE-dependent EGFR ligand shedding in breast cancer. Kenny PA, Bissell MJ, J Clin Invest 2007 117 337 345 10.1172/JCI29518 17218988 (Pubitemid 46203962)
16. ADAM-17 expression in breast cancer correlates with variables of tumor progression. McGowan PM, Ryan BM, Hill AD, McDermott E, O'Higgins N, Duffy MJ, Clin Cancer Res 2007 13 2335 2343 10.1158/1078-0432.CCR-06-2092 17438092 (Pubitemid 46698582)
17. TACE is required for the activation of the EGFR by TGF-alpha in tumors. Borrell-Pages M, Rojo F, Albanell J, Baselga J, Arribas J, EMBO J 2003 22 1114 1124 10.1093/emboj/cdg111 12606576 (Pubitemid 36313595)
18. ADAM12 is highly expressed in carcinoma-associated stroma and is required for mouse prostate tumor progression. Peduto L, Reuter VE, Sehara-Fujisawa A, Shaffer DR, Scher HI, Blobel CP, Oncogene 2006 25 5462 5466 10.1038/sj.onc. 1209536 16607276 (Pubitemid 44330288)
19. Multiple acquired renal carcinoma tumor capabilities abolished upon silencing of ADAM17. Franovic A, Robert I, Smith K, et al. Cancer Res 2006 66 8083 8090 10.1158/0008-5472.CAN-06-1595 16912185 (Pubitemid 44299174)
20. Involvement of NF-kappaB-mediated maturation of ADAM-17 in the invasion of oral squamous cell carcinoma. Takamune Y, Ikebe T, Nagano O, Shinohara M, Biochem Biophys Res Commun 2008 365 393 398 10.1016/j.bbrc.2007.11.010 17999917 (Pubitemid 350137302)
21. ADAM17 promotes breast cancer cell malignant phenotype through EGFR-PI3K-AKT activation. Zheng X, Jiang F, Katakowski M, et al. Cancer Biol Ther 2009 8 1045 1054 19395875
22. ADAM9 is involved in pathological retinal neovascularization. Guaiquil V, Swendeman S, Yoshida T, Chavala S, Campochiaro PA, Blobel CP, Mol Cell Biol 2009 29 2694 703 10.1128/MCB.01460-08 19273593
23. Potential role for ADAM15 in pathological neovascularization in mice. Horiuchi K, Weskamp G, Lum L, et al. Mol Cell Biol 2003 23 5614 24 10.1128/MCB.23.16.5614-5624.2003 12897135 (Pubitemid 36951327)
24. Connective tissue growth factor is a substrate of ADAM28. Mochizuki S, Tanaka R, Shimoda M, et al. Biochem Biophys Res Commun 2010 402 651 7 10.1016/j.bbrc.2010.10.077 20971063
25. Pathological neovascularization is reduced by inactivation of ADAM17 in endothelial cells but not in pericytes. Weskamp G, Mendelson K, Swendeman S, Le Gall S, Ma Y, Lyman S, Hinoki A, Eguchi S, Guaiquil V, Horiuchi K, Blobel CP, Circ Res 2010 106 932 40 10.1161/CIRCRESAHA.109.207415 20110534
26. ADAM8 expression is associated with increased invasiveness and reduced patient survival in pancreatic cancer. Valkovskaya N, Kayed H, Felix K, et al. J Cell Mol Med 2007 11 1162 1174 10.1111/j.1582-4934.2007.00082.x 17979891 (Pubitemid 350037057)
27. Increased mRNA expression of ADAMs in renal cell carcinoma and their association with clinical outcome. Roemer A, Schwettmann L, Jung M, et al. Oncol Rep 2004 11 529 536 14719095
28. ADAM9 Expression is a Significant and Independent Prognostic Marker of PSA Relapse in Prostate Cancer. Fritzsche FR, Jung M, Tolle A, et al. Eur Urol 2007 54 1097 106 18061337
29. Distinct Functions of Natural ADAM-15 Cytoplasmic Domain Variants in Human Mammary Carcinoma. Zhong JL, Poghosyan Z, Pennington CJ, et al. Mol Cancer Res 2008 6 383 394 10.1158/1541-7786.MCR-07-2028 18296648 (Pubitemid 351416529)
30. Expression of ADAM9 mRNA and protein in breast cancer. O'Shea C, McKie N, Buggy Y, Duggan C, Hill AD, McDermott E, O'Higgins N, Duffy MJ, Int J Cancer 2003 105 754 61 10.1002/ijc.11161 12767059 (Pubitemid 36706097)
31. ADAM-17 predicts adverse outcome in patients with breast cancer. McGowan PM, McKiernan E, Bolster F, et al. Ann Oncol 2008 19 1075 81 10.1093/annonc/mdm609 18238782 (Pubitemid 351796332)
32. Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. Zhou B-B S, Petyon M, He B, et al. Cancer Cell 2006 10 39 50 10.1016/j.ccr.2006.05.024 16843264 (Pubitemid 44018087)
33. Selective inhibition of ADAM metalloproteases as a novel approach for modulating ErbB pathways in cancer. Fridman JS, Caulder E, Hansbury M, et al. Clin Cancer Res 2007 13 1892 902 10.1158/1078-0432.CCR-06-2116 17363546 (Pubitemid 46952960)
34. Synergistic Inhibition with a dual epidermal growth factor receptor/HER-2/neu tyrosine kinase inhibitor and a disintegrin and metalloprotease inhibitor. Witters L, Scherle P, Friedman S, et al. Cancer Res 2008 68 7083 7089 10.1158/0008-5472.CAN-08-0739 18757423
35. Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands. Sahin U, Weskamp G, Kelly K, et al. J Cell Biol 2004 164 769 779 10.1083/jcb.200307137 14993236 (Pubitemid 38282960)
36. Ectodomain shedding of the EGF-receptor ligand epigen is mediated by ADAM17. Sahin U, Blobel CP, FEBS Lett 2007 581 41 44 10.1016/j.febslet.2006.11. 074 17169360 (Pubitemid 46001649)
37. Substrate selectivity of epidermal growth factor-receptor ligand sheddases and their regulation by phorbol esters and calcium influx. Horiuchi K, Le Gall S, Schulte M, et al. Mol Biol Cell 2007 18 176 88 17079736 (Pubitemid 46066719)
38. Anti-epidermal growth factor receptor monotherapy in the treatment of metastatic colorectal cancer: where are we today? Peeters M, Price T, Van Laethem JL, Oncologist 2009 14 29 39 10.1634/theoncologist.2008-0167 19144681
39. HER-2 signaling and inhibition in breast cancer. Browne BC, O'Brien N, Duffy MJ, et al. Current Cancer Drug Ther 2009 9 419 38 10.2174/ 156800909788166484
40. The EGF receptor family: spearheading a merger of signaling and therapeutics. Bublil EM, Yarden Y, Curr Opin Cell Biol 2007 19 124 34 10.1016/j.ceb.2007.02.008 17314037 (Pubitemid 46386405)
41. UV-induced EGFR signal transactivation is dependent on proligand shedding by activated metalloproteases in skin cancer cell lines. Singh B, Schneider M, Knyazev P, Ullrich A, Int J Cancer 2009 124 531 539 10.1002/ijc.23974 19003995
42. Stimulation of platelet-derived growth factor receptor beta [PDGFRbeta] activates ADAM17 and promotes metalloproteinase-dependent cross-talk between the PDGFRbeta and epidermal growth factor receptor [EGFR] signaling pathways. Mendelson K, Swendeman S, Saftig P, Blobel CP, J Biol Chem 2010 285 25024 32 10.1074/jbc.M110.102566 20529858
43. Proteolytic release of the carboxy-terminal fragment of proHB-EGF causes nuclear export of PLZF. Nanba D, Mammoto A, Hashimoto K, et al. J Cell Biol 2003 163 489 502 10.1083/jcb.200303017 14597771 (Pubitemid 37429863)
44. Suppression of proHB-EGF carboxy-terminal fragment nuclear translocation: a new molecular target therapy for gastric cancer. Shimura T, Kataoka H, Ogasawara N, et al. Clin Cancer Res 2008 14 3956 65 10.1158/1078-0432.CCR-07- 4794 18559618
45. TGFbeta signalling: a complex web in cancer progression. Ikushima H, Miyazono K, Nat Rev Cancer 2010 10 415 24 Review 10.1038/nrc2853 20495575
46. TACE-mediated ectodomain shedding of the type I TGF-beta receptor downregulates TGF-beta signaling. Liu C, Xu P, Lamouille S, Xu J, Derynck R, Mol Cell 2009 35 26 36 10.1016/j.molcel.2009.06.018 19595713
47. ADAM10 mediates E-cadherin shedding and regulates epithelial cell-cell adhesion, migration, and -catenin translocation. Maretzky T, Reiss K, Ludwig A et al, Proc Natl Sci USA 2005 102 9182 9187 10.1073/pnas.0500918102 (Pubitemid 40923538)
48. The ectodomain shedding of E-cadherin by ADAM15 supports ErbB receptor activation. Najy AJ, Day KC, Day ML, J Biol Chem 2008 283 18393 401 10.1074/jbc.M801329200 18434311
49. Tumor angiogenesis: cause or consequence of cancer? Schors K, Evan G, Cancer Res 2007 67 7059 61 10.1158/0008-5472.CAN-07-2053 17671171 (Pubitemid 47206529)
50. Pulmonary hypoplasia in mice lacking tumor necrosis factor-alpha converting enzyme indicates an indispensable role for cell surface protein shedding during embryonic lung branching morphogenesis. Zhao J, Chen H, Peschon JJ, et al. Dev Biol 2001 232 204 218 10.1006/dbio.2001.0176 11254358 (Pubitemid 32250955)
51. ADAM-17 regulates endothelial cell morphology, proliferation and in vitro angiogenesis. Gooz P, Gooz M, Baldys A, et al. Biochem Biophys Res Commun 2009 380 33 8 10.1016/j.bbrc.2009.01.013 19150341
52. Clinical uses of tumor markers: a critical review. Duffy MJ, Crit Rev Clin Lab Sci 2001 38 225 262 10.1080/20014091084218 11451209 (Pubitemid 32614076)
53. ADAM 12 cleaves extracellular matrix proteins and correlates with cancer status and stage. Roy R, Wewer UM, Zurakowski D, Pories SE, Moses MA, J Biol Chem 2004 279 51323 30 10.1074/jbc.M409565200 15381692 (Pubitemid 40017878)
54. Urinary metalloproteinases: noninvasive biomarkers for breast cancer risk assessment. Pories SE, Zurakowski D, Roy R, Lamb CC, Raza S, Exarhopoulos A, Scheib RG, Schumer S, Lenahan C, Borges V, Louis GW, Anand A, Isakovich N, Hirshfield-Bartek J, Wewer U, Lotz MM, Moses MA, Cancer Epidemiol Biomarkers Prev 2008 17 1034 42 10.1158/1055-9965.EPI-07-0365 18483323
55. Serum tumor markers in breast cancer: are they of clinical value? Duffy MJ, Clin Chem 2006 52 345 51 10.1373/clinchem.2005.059832 16410341
56. Molecular profiling of ADAM12 in human bladder cancer. Fröhlich C, Albrechtsen R, Dyrskjøt L, Rudkjaer L, rntoft TF, Wewer UM, Clin Cancer Res 2006 12 7359 68 10.1158/1078-0432.CCR-06-1066 17189408 (Pubitemid 46095409)
57. ADAM28 is a serological and histochemical marker for non-small-cell lung cancers. Kuroda H, Mochizuki S, Shimoda M, Chijiiwa M, Kamiya K, Izumi Y, Watanabe M, Horinouchi H, Kawamura M, Kobayashi K, Okada Y, Int J Cancer 2010
58. ADAM9 expression in pancreatic cancer is associated with tumour type and is a prognostic factor in ductal adenocarcinoma. Grützmann R, Lüttges J, Sipos B, Ammerpohl O, Dobrowolski F, Alldinger I, Kersting S, Ockert D, Koch R, Kalthoff H, Schackert HK, Saeger HD, Klöppel G, Pilarsky C, Br J Cancer 2004 90 1053 8 10.1038/sj.bjc.6601645 14997207 (Pubitemid 38495828)
59. Predictive markers in breast and other cancers: a review. Duffy MJ, Clin Chem 2005 51 494 503 10.1373/clinchem.2004.046227 15637130 (Pubitemid 40300223)
60. How ADAM-9 and ADAM-11 differentially from estrogen receptor predict response to tamoxifen treatment in patients with recurrent breast cancer: a retrospective study. Sieuwerts AM, Meijer-van Gelder ME, Timmermans M, Trapman AM, Garcia RR, Arnold M, Goedheer AJ, Portengen H, Klijn JG, Foekens JA, Clin Cancer Res 2005 11 7311 21 10.1158/1078-0432.CCR-05-0560 16243802 (Pubitemid 41507689)
61. The ADAM10 prodomain is a specific inhibitor of ADAM10 proteolytic activity and inhibits cellular shedding events. Moss ML, Bomar M, Liu Q, et al. J Biol Chem 2007 282 35712 21 10.1074/jbc.M703231200 17895248 (Pubitemid 350277116)
62. Gonzales PE, Solomon A, Miller AB, et al. J Biol Chem 2004 279 31638 31645 Kveiborg M, Jacobsen J, Lee M-H, et al. Inhibition of the tumor necrosis factor-alpha-converting enzyme by its pro domain. J Biol Chem 2004, 279:31638-45 10.1074/jbc.M401311200 15100227 (Pubitemid 39037834)
63. The isolated N-terminal domains of TIMP-1 and TIMP-3 are insufficient for ADAM10 inhibition. Rapti M, Atkinson SJ, Lee MH, Trim A, Moss M, Murphy G, Biochem J 2008 411 433 9 10.1042/BJ20071430 18215140 (Pubitemid 351580196)
64. Selective inhibition of ADAM12 catalytic activity through engineering of tissue inhibitor of metalloproteinase 2 [TIMP-2]. Kveiborg M, Jacobsen J, Lee MH, Nagase H, Wewer UM, Murphy G, Biochem J 2010 430 79 86 10.1042/BJ20100649 20533908
65. Increased expression of ADAM family members in human breast cancer and breast cancer cell lines. Lendeckel U, Kohl J, Arndt M, et al. J Clin Res Clin Oncol 2005 131 41 8 10.1007/s00432-004-0619-y
66. Synthesis and structure-activity relationship of a novel achiral series of TNF-alpha converting enzyme inhibitors. Gilmore JL, King BW, Harris K, et al. Bioorganic Med Chem 2006 16 2699 704 10.1016/j.bmcl.2006.02.015
67. Acetylenic TACE inhibitors. Levin JI, Chen JM, Laakso LM, et al. Part 3: thiomorpholine sulfonamide hydroxamates. Bioorganic Med Chem Lett 2006 16 1605 09
68. Drug insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis. Moss ML, Sklair-Tavron L, Nudelman R, Nat Clin Pract Rheumatol 2008 4 300 9 10.1038/ncprheum0797 18414459 (Pubitemid 351791441)
69. ADAM10 as a target for anti-cancer therapy. Moss ML, Stoeck A, Yan W, Dempsey PJ, Curr Pharm Biotechnol 2008 9 2 8 10.2174/138920108783497613 18289051 (Pubitemid 351266964)
70. Preclinical characterization of INCB7839, a potent and selective inhibitor of ErbB ligand and HER2 receptor shedding: inhibition of ADAM10 and ADAM17 for the treatment of breast cancer. Fridman JS, Scherle PA, Liu X, et al. Breast Cancer Res Treat 2007 106 Supp1 82
71. A multicenter phase Ib study of the safety, pharmacokinetics, biological activity and clinical efficacy of INCB7839, a potent and selective inhibitor of ADAM10 and ADAM17. Infante J, Burris HA, Lewis N, et al. Breast Cancer Res Treat 2007 106 Supp1 269
72. Clinical benefit of INCB7839, a potential and selective ADAM inhibitor, in combination with trastuzumab in patients with metastatic HER2-positive breast cancer. Newton RC, Bradley EC, Levy RS, et al. J Clin Oncol 2010 28 Suppl; abst 3025 7s
73. TACE/ADAM-17: a component of epidermal growth factor receptor axis and a promising therapeutic target in colorectal cancer. Merchant NB, Voskresensky I, Rogers CM, et al. Clin Cancer Res 2008 14 1182 191 10.1158/1078-0432.CCR-07-1216 18281553 (Pubitemid 351302567)
74. The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 [fractalkine] and regulates CX3CL1-mediated cell-cell adhesion. Hundhausen C, Misztela D, Berkhout TA, Broadway N, Saftig P, Reiss K, Hartmann D, Fahrenholz F, Postina R, Matthews V, Kallen KJ, Rose-John S, Ludwig A, Blood 2003 102 1186 95 10.1182/blood-2002-12-3775 12714508 (Pubitemid 36988021)
75. Characterization of [2R, 3S]-2-[[[4-[2-butynyloxy]phenyl]sulfonyl]amino]- N,3-dihydroxybutanamide, a potent and selective inhibitor of TNF-alpha converting enzyme. Zhang Y, Hegen M, Xu J, et al. Int Immunopharmacol 2004 4 1845 1857 10.1016/j.intimp.2004.08.003 15531300 (Pubitemid 39504825)
76. Matrix metalloproteinases as valid clinical targets. Fingleton B, Current Pharm Design 2007 13 333 46 10.2174/138161207779313551 (Pubitemid 46085282)
77. Critical appraisal of the use of matrix metalloproteinases inhibitors in cancer treatment. Zucker S, Cao J, Chen W-T, Oncogene 2000 19 6642 650 10.1038/sj.onc.1204097 11426650 (Pubitemid 32197703)
78. Phase II study of weakly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu overexpressing metastatic breast cancer. Baselga J, Tripathy D, Mendelsohn J, et al. J Clin Oncol 1996 14 737 744 8622019
79. Multinational study of the efficiacy and safety of humanised anti-HER2 monoclonal antibody in women who have HER2 overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, et al. J Clin Oncol 1999 17 2639 2648 10561337 (Pubitemid 29415219)
80. Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy. Asakura M, Kitakaze M, Takashima S, et al. Nat Med 2002 8 35 40 10.1038/nm0102-35 11786904 (Pubitemid 34101726)